A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
A phase 1/2 trial of AZD9750, Saruparib in prostate cancer, run by AstraZeneca, now recruiting.
Overview
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs is a phase 1/2 interventional study registered as NCT07336446 by AstraZeneca, with 300 participants planned, started 2026-01-27 and due to reach its primary completion in 2029-01-26. Interventions recorded: AZD9750, AZD5305. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialSaruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Shares Saruparib, AstraZeneca, Prostate cancer.
- TrialA Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Shares Saruparib, AstraZeneca, Prostate cancer.
- TrialStudy of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours
Shares Saruparib, AstraZeneca.
- TrialStudy of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
Shares Saruparib, AstraZeneca, Prostate cancer.
- TrialStudy of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
Shares Saruparib, AstraZeneca, Prostate cancer.
- TrialSaruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Shares Saruparib, AstraZeneca.
- TrialA Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Shares Saruparib, AstraZeneca.
- TrialPhase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Shares Saruparib, AstraZeneca.